Yahoo
NasdaqGM - Nasdaq Real Time Price USD

CAMP4 THERAPEUTICS CORPORATION (CAMP)

3.7900 -0.1700 (-4.29%)
At close: 4:00:01 PM EDT
3.7900 0.0000 (0.00%)
After hours: 4:10:04 PM EDT
Trade CAMP on Coinbase
Chart Range Bar
Loading chart for CAMP
  • Previous Close 3.9600
  • Open 3.8500
  • Bid 2.9400 x 200
  • Ask 5.4600 x 200
  • Day's Range 3.7005 - 3.9500
  • 52 Week Range 1.4100 - 7.7500
  • Volume 229,290
  • Avg. Volume 253,311
  • Market Cap (intraday) 237.835M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.3100
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 9.92

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

www.camp4tx.com

48

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CAMP
38.17%
S&P 500 (^GSPC)
11.48%

1-Year Return

CAMP
149.34%
S&P 500 (^GSPC)
18.13%

3-Year Return

CAMP
66.04%
S&P 500 (^GSPC)
69.00%

5-Year Return

CAMP
66.04%
S&P 500 (^GSPC)
68.69%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.29M
Earnings -18.33M
Profit Margin -1,416.62%

Q3

FY25

Q4

FY25

Q1

FY26

-40M
-30M
-20M
-10M
0
-10000.0%
-8000.0%
-6000.0%
-4000.0%
-2000.0%

Analyst Insights

View More

Analyst Price Targets

6.50
9.92 Average
3.7900 Current
15.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst Piper Sandler
Rating Action Reiterates
Rating Overweight
Price Action Raises
Price Target 12 -> 15

Statistics

View More

Valuation Measures

Annual
As of 8/31/2026
  • Market Cap

    249.13M

  • Enterprise Value

    165.10M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    46.39

  • Price/Book (mrq)

    9.11

  • Enterprise Value/Revenue

    39.16

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.25%

  • Return on Equity (ttm)

    -545.85%

  • Revenue (ttm)

    4.22M

  • Net Income Avi to Common (ttm)

    -107.24M

  • Diluted EPS (ttm)

    -2.3100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    86.4M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -12.83M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

3.7900 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: